Skye Bioscience Inc (SKYE)

[Paulieme]

Aug. 18 issue of BioWorld.--- Can cannabinoids earn respect? New candidates not just blowing smoke! Companies such as GW Pharmaceuticals plc and Insys Therapeutics Inc. continue to use the native tetrahydrocannabinol (THC) molecule formulated for oral administration, observed Brian Murphy, CEO and chief medical officer of Nemus Bioscience Inc., of Costa Mesa, Calif. In contrast, "companies like Zynerba [Pharmaceuticals] and Nemus are developing bioengineered cannabinoids for a more optimized route of administration in a more effective manner, so that blood levels associated with that administration stay more reliably within the therapeutic window."

Oral administration also requires developers of cannabinoid therapies to contend with a drug's metabolism in the liver, where miscalculation in dosing or in drug-drug or food-drug interactions could lead to inter- and/or intra-patient variation, he added. Using synthetic manufacturing, Nemus is addressing those issues to ensure reliable pharmacokinetics and bioavailability. http://www.bioworld.com/content/can-cannabinoids-earn-respect-new-candidates-not-just-blowing-smoke